Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery

The Effect of Dexmedetomidine on Neuroprotection in Pediatric Cardiac Surgery Patients: a Randomized Controlled Trial

Neurodevelopmental disability is the most significant complication for survivors of infant surgery for congenital heart disease. In this study we sought to determine if intraoperative continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12 months.

Inclusion Criteria:

• Neonates undergoing cardiac surgery
• Infants undergoing cardiac surgery with cardiopulmonary bypass (atrial septal defect repair, ventricular septal defect repair, or tetralogy of fallot repair)

Exclusion Criteria:

• History of hypersensitivity of any drug
• Presence of hypotension or bradycardia considering age Bradycardia (heart rate < 80 beats/min) or hypotension (systolic blood pressure < 70mmHg for infants, < 60mmHg for neonates)
• Elevated liver enzyme levels (aspartate transaminase >100unit/L, alanine aminostrasferase > 50 unit/L)
• surgery with deep hypothermic circulatory arrest
• Presence of complex cardiac defect
• single ventricular physiology
• plan of additional operation within a year
• preoperative use of beta-agonists
• presence of history of any neurological disorder